Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Mitrovi A
Retatrutide Sexual Function Impact: What the Phase 2 Data Actually Show At a glance Drug / retatrutide (LY3437943), investigational triple GIP/GLP-1/glucagon receptor agonist Phase 2 trial / Jastreboff et al., NEJM 2023, N=338 adults with obesity Peak weight loss / 24.2% mean body-weight reduction at 48 weeks (12 mg dose) Sexual-function endpoints / not prespecified in Phase 2
The practical comparison: Neither form is universally superior
US$ 22.93
US$ 24.97
US$ 23.36
US$ 23.38
US$ 22.50
US$ 22.75
US$ 23.77
US$ 25.76
US$ 23.89
